India defers Mylan's Agila deal but Q4 close on course
This article was originally published in Scrip
Executive Summary
India's Foreign Investment Promotion Board (FIPB) has deferred a decision on three foreign direct investment (FDI) proposals, including Mylan's $1.6bn-plus acquisition of Strides Arcolab's injectables arm, Agila Specialties, amid general concerns by the department of industrial policy and promotion (DIPP) over deals that may have a potential impact on India's medicines security.